Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy in HER2-positive gastric or GEJ adenocarcinoma
2023-508253-98-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Pembrolizumab + trastuzumab + chemotherapy with Placebo + trastuzumab + chemotherapy (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-508253-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508253-98-00.